Strategies to prolong drug retention in solid tumors by aggregating Endo-CMC nanoparticles

J Control Release. 2023 Aug:360:705-717. doi: 10.1016/j.jconrel.2023.07.006. Epub 2023 Jul 19.

Abstract

Developing a highly effective nano-drug delivery system with sufficient drug permeability and retention in tumors is still a major challenge for oncotherapy. Herein, a tumor microenvironment responsive, aggregable nanocarriers embedded hydrogel (Endo-CMC@hydrogel) was developed to inhibit the tumoral angiogenesis and hypoxia for enhanced radiotherapy. The antiangiogenic drug (recombinant human endostatin, Endo) loaded carboxymethyl chitosan nanoparticles (Endo-CMC NPs) was wrapped by 3D hydrogel to comprise the Endo-CMC@hydrogel. After peritumoral injection, the Endo-CMC NPs were released, invaded deeply into the solid tumor, and cross-linked with intratumoral calcium ions. The cross-linking process enabled these Endo-CMC NPs to form larger particles, leading to long retention in tumor tissue to minimize premature clearance. This Endo-CMC@hydrogel, integrating the abilities of good tumoral penetration, long retention of anti-drug, and alleviation of hypoxia in tumor tissue, greatly improved the therapeutic effect of radiotherapy. This work provides a proof-of-concept of tumor microenvironment-responding and an aggregable nano-drug delivery system as promising antitumor drug carriers for effective tumor therapy.

Keywords: Aggregable nanoparticles; Carboxymethyl chitosan; Peritumoral injection; Radiotherapy; Vascular normalization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Chitosan* / administration & dosage
  • Drug Carriers
  • Humans
  • Hydrogels
  • Nanoparticle Drug Delivery System
  • Nanoparticles*

Substances

  • Antineoplastic Agents
  • Chitosan
  • Drug Carriers
  • Hydrogels
  • Nanoparticle Drug Delivery System